The content on this site is intended for healthcare professionals only
In a press conference at SABCS 2014, Dr Sikov presents the results of his work on combination therapies based on cancer subtype.
Among women with triple-negative breast cancer, the benefit of adding bevacizumab to standard presurgery chemotherapy was greater for those whose cancers were classified as "basal-like" compared with those whose cancers were "nonbasal-like."
Read the news story or watch the interview for more. Also see comment from Prof Arteaga.
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Highlights and analysis
ESMO 2024: Latest in EGFR mutated NSCLC
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
OncoAlert round up July 28th to August 3rd, 2023
Updates on triple-negative breast cancer and immunotherapy
Management of HER2 positive metastatic breast cancer treatment algorithm
